CRITICAL APPRAISAL OF ARTICLE ON HARM. Among patients with acute rheumatic fever, will administration of non steroidal anti- inflammatory drugs have adverse.

Slides:



Advertisements
Similar presentations
Evidence Based Practice MMR Vaccine Who Has Concerns About the Safety of This Vaccine?
Advertisements

CRITICAL APPRAISAL ON AN ARTICLE ABOUT PROGNOSIS
NSAIDs and GI and Renal Complications Lessons from Tennessee Medicaid population studies (and selected others)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen.
Evidence-Based Medicine Critical Appraisal of Therapy Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences.
Case-Control Studies (Retrospective Studies). What is a cohort?
Australasian Society of Clinical Immunology and Allergy Adverse Reactions to NSAIDs David Henry Faculty of Medicine and Health Sciences The University.
Presentations in this series 1.Introduction 2.Self-matching 3.Proxies 4.Intermediates 5.Instruments 6.Equipoise Avoiding Bias Due to Unmeasured Covariates.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.
Objective What is EBM. How to apply it. How to make evidence base presentation.
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
Evidence-based Medicine Journal Club Khalid Bin Abdulrahman Director of Medical Education Center King Saud University.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2010.
Journal Club Alcohol and Health: Current Evidence May-June 2006.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
OPPORTUNITIES FOR RESEARCH IN PRIMARY CARE Jen Dumbleton Clinical Trial Manager University of Nottingham
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
WEEK 3 RECAP. Evidence Based Practice What is it? “Process in which practioners make practice decisions in light of the best research evidence available”
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2012.
Clinical Appraisal of an Article on Prognosis The Clinical Question Will the prognosis of patients with gout be affected by the administration allupurinol?
HelpDesk Answers Dissecting the Clinical Question
Clinical Appraisal of an Article on Prognosis. The Clinical Question What is the risk of mortality among patients with hyperuricemia who received allupurinol?
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
Critical Appraisal of a Randomized Controlled Trail By ANNERIE HATTINGH 07 January 2009.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.
AUA VUR guidelines 2010 Methodology Twenty-one studies met the inclusion criteria (six were prospective), data were extracted and a meta-analysis was.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
CAT 3 Harm, Causation Maribeth Chitkara, MD Rachel Boykan, MD.
+ Clinical Decision on a Diagnostic Test Inna Mangalindan. Block N. Class September 15, 2008.
Critical Appraisal of an Article on HARM. Clinical Question Is there potential harm after administering allopurinol in patients with gout and azotemia?
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
CRITICAL APPRAISAL OF ARTICLE ON HARM. Among patients with acute rheumatic fever, will discontinuation of penicillin have adverse effects? Clinical question.
Wipanee Phupakdi, MD September 15, Overview  Define EBM  Learn steps in EBM process  Identify parts of a well-built clinical question  Discuss.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Critical Appraisal of an Article on HARM. Clinical Question Is there potential harm after administering allopurinol in patients with gout and azotemia?
Clinical Decision on Harm. Clinical scenario or question Will laparoscopic hysterectomy increase post operative complications for our obese patient with.
HARM APPRAISAL. Is the objective of the article on harm similar to your clinical dilemma?
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2015.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
RELEVANCERELEVANCE Is the objective of the article on harm similar to your clinical dilemma? Yes, the article’s objective is similar to the clinical dilemma.
Summary Pattern of Specific COX II Inhibitors Use Physician prescribed appropriate COX II use in high risk was 40.08% and inappropriate COX II use in low.
CLINICAL EPIDEMIOLOGY III: JOURNAL APPRAISAL Group 3 February 11, 2010.
Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 20, 2002.
What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast NSAIDS – Efficacy and Safety Expert speaker.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Once-Daily Celecoxib Effective for Preventing Sporadic Colorectal Adenomas Slideset on: Arber N, Rácz I, Spicak J, et al. Chemoprevention of colorectal.
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases
NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Pain treatment How drugs work on pain.
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Galileo.
Selection of NSAIDs for Osteoarthritis
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 
Vascular Overviews Group
EBM --- Journal Reading
Evidence Based Practice
Presentation transcript:

CRITICAL APPRAISAL OF ARTICLE ON HARM

Among patients with acute rheumatic fever, will administration of non steroidal anti- inflammatory drugs have adverse effects? Clinical question patients with rheumatic fever taking NSAIDs Population: non steroidal anti-inflammatory drugs Intervention: Harm, complications Outcome: Incidence of Serious Upper Gastrointestinal Bleeding in patients taking Non Steroidal Anti-inflammatory Drugs in Japan Ishikawa SIshikawa S, Inaba T, Mizuno M, Okada H, Kuwaki K, Kuzume T,Inaba TMizuno MOkada HKuwaki KKuzume T Search terms: gastrointestinal bleeding, non steroidal anti-inflammatory drugs, salicylates, rheumatic fever

Relevance Yes. The objective of the study is to determine the annual incidence of serious upper gastrointestinal bleeding among Japanese patients in whom NSAIDs were used while the recommended treatment for our patient in this case which is salicylate falls under this drug family. (page 29,Abstract,1 st paragraph) Is the objective of the article similar to your dilemma?

Validity Yes. The investigator only included patients who were 30 – 70 yrs old, from both sexes who were taking NSAIDs for cardiovascular disease, cerebrovascular disease, arthritis, fever and pain control. The subjects were categorized as a) patients on low dose aspirin and b)patients on non aspirin NSAIDs. (page 30,Materials and Methods, 2 nd paragraph) (page 31,Results, 1 st paragraph) Were there clearly identified comparison groups? Yes. The exposures and outcomes were measured in the same way in the groups compared. The outcomes of all groups were determined through endoscopic examination of bleeding ulcers in all groups. (page 30, Materials and Methods, 4 th paragraph) Were the exposures and outcomes measured in the same way in the groups compared?

Yes. Follow up was done after two years from the start of administration of non steroidal anti – inflammatory drugs which is from June 2003 to June (page 30, Materials and Methods, 2 nd paragraph) 18,048 subjects were identified in the study. 629 were lost to follow up whie 148 died of other causes. Of the remaining 17,270, 8,815 periodically came for hospital visits, 7,613 returned after their last NSAID prescription, 992 were interviewed by telephone. They therefore have a 96 % follow up. (page 31, Results, 2 nd paragraph) Was follow-up sufficiently long and complete?

Yes. The study administered NSAIDs before any event of bleeding ulcer so the temporal relationship was correct. (page 30, Table 1) NSAIDs used in this study were low dose aspirin ( m; Bufferin 81mg and Bayaspirin, a 100mg enteric coated tablet) and other NSAID (page 30, Table 2) Is the temporal relationship between the exposure and outcome correct and dose response gradient present? Since all the answers for the validity guides are valid, the study can be considered valid. Overall, is the study valid?

Results Incidence rate for bleeding: 2.65 (95% CI, ) per 1,000 patient years for low dose aspirin 1.29 (95% CI, 1.32) per 1,000 patient years non- aspirin NSAID users (page 33, Results, 2 nd paragraph) Incidence rate for bleeding: 2.65 (95% CI, ) per 1,000 patient years for low dose aspirin 1.29 (95% CI, 1.32) per 1,000 patient years non- aspirin NSAID users (page 33, Results, 2 nd paragraph) What is the magnitude of the association between exposure and outcome? Was the estimate of the risk precise?

Clinical Applicability Yes. (page 30, Materials & Methods, 1 st paragraph) anti-inflammatory agent in the treatment of symptomatic acute rheumatic fever Incidence of assoc. upper GI ulcer bleeding was low and outcomes did not become serious when adequate measures were taken to prevent bleeding (page 33-34, Discussion) no alternative treatments mentioned recommended that anti-ulcer agents like PPIs or H2RA be co-administered to prevent serious adverse events associated with NSAID use (page 33, Discussion, 1 st paragraph) 28 year-old female cardiovascular problem chest pain, fever and arthritis mean age : 51.5± 20.7 years indications for NSAID (fever, pain, arthritis, CV disease Are the study patients similar to my own? What is our patient’s risk of benefit and harm from the exposure? What alternative treatments are available?

Resolution to the Scenario Based on the appraisal, the patient will be advised to continue treatment with aspirin or other non-aspirin NSAIDs provided that anti- ulcer agents like proton-pump inhibitors and H2 blockers are also administered.